{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:48:35Z","timestamp":1794646115148,"version":"4.9.1"},"reference-count":44,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,3,16]],"date-time":"2010-03-16T00:00:00Z","timestamp":1268697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Tumour lysis syndrome (TLS) is a life\u2010threatening oncological emergency characterized by metabolic abnormalities including hyperuricaemia, hyperphosphataemia, hyperkalaemia and hypocalcaemia. These metabolic complications predispose the cancer patient to clinical toxicities including renal insufficiency, cardiac arrhythmias, seizures, neurological complications and potentially sudden death. With the increased availability of newer therapeutic targeted agents, such as rasburicase (recombinant urate oxidase), there are no published guidelines on the risk classification of TLS for individual patients at risk of developing this syndrome. We convened an international TLS expert consensus panel to develop guidelines for a medical decision tree to assign low, intermediate and high risk to patients with cancer at risk for TLS. Risk factors included biological evidence of laboratory TLS (LTLS), proliferation, bulk and stage of malignant tumour and renal impairment and\/or involvement at the time of TLS diagnosis. An international TLS consensus expert panel of paediatric and adult oncologists, experts in TLS pathophysiology and experts in TLS prophylaxis and management, developed a final model of low, intermediate and high risk TLS classification and associated TLS prophylaxis recommendations.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2010.08143.x","type":"journal-article","created":{"date-parts":[[2010,3,16]],"date-time":"2010-03-16T04:10:36Z","timestamp":1268712636000},"page":"578-586","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":478,"title":["Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus"],"prefix":"10.1111","volume":"149","author":[{"given":"Mitchell S.","family":"Cairo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Coiffier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Younes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the TLS Expert Panel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,4,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/02841860701367860"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000054661"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(75)90597-5"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00280-002-0556-x","article-title":"Acute tumor lysis syndrome in solid tumors\u2010\u2010a case report and review of the literature","volume":"51","author":"Baeksgaard L.","year":"2003","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e318162bd41"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11612"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05094.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000118524"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2008.n.003"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e31818ab30c"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.7.2313"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-008-0642-1"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0177"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196603032740902"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.3816\/SCT.2003.n.003"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199412000-00010"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2009.03.060"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90174-N"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7308.334"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12327"},{"key":"e_1_2_8_22_1","first-page":"50","article-title":"Acute spontaneous tumor lysis presenting with hyperuricemic acute renal failure: clinical features and therapeutic approach","volume":"17","author":"Hsu H.H.","year":"2004","journal-title":"Journal of Nephrology"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00550.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10283"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00153-8"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.47.1456"},{"key":"e_1_2_8_27_1","first-page":"53","article-title":"Optimizing the use of rituximab for treatment of B\u2010cell non\u2010Hodgkin\u2019s lymphoma: a benefit\u2010risk update","volume":"27","author":"Kunkel L.","year":"2000","journal-title":"Seminars in Oncology"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197503202921208"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2002.s.011"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2008.s.009"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-008-9064-0"},{"key":"e_1_2_8_32_1","first-page":"61","article-title":"Incidence and pathogenesis of tumor lysis syndrome","volume":"147","author":"Locatelli F.","year":"2005","journal-title":"Contributions to Nephrology"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.3816\/SCT.2005.n.008"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11575"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402847"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-168583"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1043892"},{"key":"e_1_2_8_38_1","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1542\/peds.82.6.863","article-title":"Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma","volume":"82","author":"Stapleton F.B.","year":"1988","journal-title":"Pediatrics"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13290"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22990"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-198105000-00005"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002770000276"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-200301000-00008"},{"key":"e_1_2_8_44_1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00277-003-0608-2","article-title":"Incidence of tumor lysis syndrome in children with advanced stage Burkitt\u2019s lymphoma\/leukemia before and after introduction of prophylactic use of urate oxidase","volume":"82","author":"Wossmann W.","year":"2003","journal-title":"Annals of Hematology"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C336"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2010.08143.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2010.08143.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T19:30:07Z","timestamp":1697398207000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2010.08143.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,25]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1111\/j.1365-2141.2010.08143.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08143.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,25]]},"assertion":[{"value":"2010-04-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}